Close Menu

NEW YORK – Although liquid biopsy — mostly circulating tumor DNA assays — is increasingly being investigated for early-stage cancer, the jury remains very much out on whether it can actually improve patient outcomes by guiding the right individuals to adjuvant therapies or helping them avoid unnecessary treatments.

However, a report published earlier this month in Nature Cancer has added important new evidence that this might be possible, in at least some settings.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.